Alprolix 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
II/0036/G 
This was an application for a group of variations. 
09/09/2021 
Annex II 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test method 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are 
issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD 
is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
at the site is a biol/immunol method 
B.I.a.1.e - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS - The 
change relates to a biological AS or a starting material 
[-] used in the manufacture of a 
biological/immunological product 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test method 
at the site is a biol/immunol method 
B.I.a.1.j - Change in the manufacturer of AS or of a 
starting material/reagent/intermediate for AS -  
Replacement or addition of a site where batch 
control/testing takes place and any of the test method 
at the site is a biol/immunol method 
IA/0037 
A.5.b - Administrative change - Change in the name 
17/05/2021 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
R/0032 
Renewal of the marketing authorisation. 
10/12/2020 
11/02/2021 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of Alprolix 
and PL 
in the approved indication remains favourable and therefore 
recommended the renewal of the marketing authorisation 
with unlimited validity. 
IB/0035 
B.I.b.2.e - Change in test procedure for AS or starting 
18/12/2020 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
Page 2/8 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0034 
B.II.z - Quality change - Finished product - Other 
28/10/2020 
n/a 
variation 
IB/0033 
B.I.d.1.a.4 - Stability of AS - Change in the re-test 
28/10/2020 
n/a 
period/storage period - Extension or introduction of a 
re-test period/storage period supported by real time 
data 
II/0029 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
03/09/2020 
19/10/2020 
SmPC and PL 
Update of sections 4.2, 4.8 and 5.1 of the SmPC as well as PL 
new quality, preclinical, clinical or pharmacovigilance 
data 
section 4 to include paediatric data on Previously Untreated 
Patients (PUPs) following the completion of a phase III study 
998HB303. 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
01/10/2020 
n/a 
PRAC Recommendation - maintenance 
/202003 
eftrenonacog alfa 
IB/0031 
B.I.b.2.e - Change in test procedure for AS or starting 
13/07/2020 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
II/0028 
B.II.d.1.e - Change in the specification parameters 
12/03/2020 
n/a 
and/or limits of the finished product - Change outside 
the approved specifications limits range 
II/0026 
B.II.b.1.c - Replacement or addition of a 
12/12/2019 
n/a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch 
release/control, and secondary packaging, for 
biol/immunol medicinal products or pharmaceutical 
forms manufactured by complex manufacturing 
Page 3/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
processes 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
03/10/2019 
n/a 
PRAC Recommendation - maintenance 
/201903 
eftrenonacog alfa 
IAIN/0027 
B.II.b.1.a - Replacement or addition of a 
26/08/2019 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
IB/0024 
B.I.b.2.e - Change in test procedure for AS or starting 
08/05/2019 
n/a 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
11/04/2019 
n/a 
PRAC Recommendation - maintenance 
/201809 
eftrenonacog alfa 
II/0021 
Update of sections 4.8 and 5.1 of the SmPC to include 
21/02/2019 
11/02/2020 
SmPC, 
Labelling and 
PL 
new clinical efficacy and safety data on long-term 
treatment with Alprolix. The submission includes 
integrated evaluation of data from the extension study 
9HB01EXT (BYOND) which was submitted in a 
previous P46 procedure and the pivotal parent studies. 
The PL is updated accordingly. In addition, the MAH 
took the opportunity to update the product 
information to comply with the latest version of the 
“Excipients in the labelling and package leaflet of 
medicinal products for human use"guideline. The list 
of local representatives has been updated and other 
minor editorial changes have been included in the PL. 
Page 4/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IA/0023 
A.5.b - Administrative change - Change in the name 
17/01/2019 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
II/0020 
B.II.b.2.b - Change to importer, batch release 
22/11/2018 
n/a 
arrangements and quality control testing of the FP - 
Replacement/addition of a site where batch 
control/testing takes place for a biol/immunol product 
and any of the test methods at the site is a 
biol/immunol method 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
04/10/2018 
n/a 
PRAC Recommendation - maintenance 
/201803 
eftrenonacog alfa 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
26/04/2018 
06/07/2018 
SmPC 
Refer to Scientific conclusions and grounds recommending 
/201709 
eftrenonacog alfa 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/10499/201709. 
IA/0018 
A.7 - Administrative change - Deletion of 
18/04/2018 
n/a 
manufacturing sites 
IB/0017 
B.I.a.4.z - Change to in-process tests or limits applied 
21/03/2018 
n/a 
during the manufacture of the AS - Other variation 
IB/0016 
B.I.b.1.i - Change in the specification parameters 
15/03/2018 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Where there is no 
Page 5/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
monograph in the European/National Ph. for the AS, a 
change in specification from in-house to a 
non-official/third country Ph. 
IB/0015 
B.II.b.5.z - Change to in-process tests or limits applied 
05/03/2018 
n/a 
during the manufacture of the finished product - Other 
variation 
IB/0014 
B.II.z - Quality change - Finished product - Other 
23/01/2018 
n/a 
variation 
IB/0012 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf life 
15/12/2017 
n/a 
of the finished product - As packaged for sale 
(supported by real time data) 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
28/09/2017 
n/a 
PRAC Recommendation - maintenance 
/201703 
eftrenonacog alfa 
IA/0010 
A.7 - Administrative change - Deletion of 
20/07/2017 
n/a 
manufacturing sites 
II/0006/G 
This was an application for a group of variations. 
20/07/2017 
n/a 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process of 
the AS 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process of 
the AS 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
Page 6/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.2.c - Changes in the manufacturing process of 
the AS - The change refers to a [-] substance in the 
manufacture of a biological/immunological substance 
which may have a significant impact on the medicinal 
product and is not related to a protocol 
B.I.a.4.z - Change to in-process tests or limits applied 
during the manufacture of the AS - Other variation 
B.I.b.2.e - Change in test procedure for AS or starting 
material/reagent/intermediate - Other changes to a 
test procedure (including replacement or addition) for 
the AS or a starting material/intermediate 
B.I.c.1.c - Change in immediate packaging of the AS - 
Liquid ASs (non sterile) 
B.II.b.3.c - Change in the manufacturing process of 
the finished or intermediate product - The product is a 
biological/immunological medicinal product and the 
change requires an assessment of comparability 
IB/0009 
B.I.a.1.k - Change in the manufacturer of AS or of a 
20/06/2017 
n/a 
starting material/reagent/intermediate for AS - New 
storage site of MCB and/or WCB 
IB/0007 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/06/2017 
07/06/2018 
SmPC, 
Veterinary Medicinal Products - Other variation 
Labelling and 
PL 
PSUSA/10499
Periodic Safety Update EU Single assessment - 
20/04/2017 
23/06/2017 
Refer to Scientific conclusions and grounds recommending 
/201609 
eftrenonacog alfa 
the variation to terms of the Marketing Authorisation(s)’ for 
Page 7/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/10499/201609. 
IB/0002 
B.I.b.1.c - Change in the specification parameters 
14/12/2016 
n/a 
and/or limits of an AS, starting 
material/intermediate/reagent - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
N/0004 
Minor change in labelling or package leaflet not 
26/10/2016 
23/06/2017 
Labelling 
connected with the SPC (Art. 61.3 Notification) 
IAIN/0003 
B.II.b.1.a - Replacement or addition of a 
17/10/2016 
n/a 
manufacturing site for the FP - Secondary packaging 
site 
T/0001 
Transfer of marketing authorisation from Biogen Idec 
25/08/2016 
30/09/2016 
SmPC, 
Ltd to Swedish Orphan Biovitrum AB (publ). 
Transfer of Marketing Authorisation 
Labelling and 
PL 
Page 8/8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
